Market By Device Type, Route Of Administration, End-user, And Region | Forecast 2019-2028
The detailed analysis of the global injectable drug delivery market shows that, in terms of revenue, the industry is estimated to grow at a CAGR of 8.66% during the forecasting years 2019-2028. It garnered a revenue of $20.48 billion in 2019, and is expected to accumulate $43.23 billion by 2028. Injectable delivery systems directly inject or administer the drug into the body of the patient apart from the oral route. Initial injection devices consisted of hypodermic needles and syringes. These first-generation devices were motorized and were used to only direct the drug into the body.
Consequently, there was an increase in the adaptability of the biologics, and the developments in prefilled syringes have supported the growth of the injectable drug delivery market. The significant technological developments related to prefilled syringes include the introduction of needlestick safety-equipped devices, advanced lubrication technology, and the use of multi?chamber syringes. Also, the changes in lifestyle have led to an increased predisposition to diseases. The higher prevalence of autoimmune diseases will ultimately lead to the increased demand for treatments and devices that can provide a better quality of life to the patients.
Report scope can be customized per your requirements. Request For Customization
The study aims to get an overview of the injectable drug delivery market in terms of various factors. Within this report, the market definition and the key insights regarding the injectable drug delivery industry have been discussed. Also, Porter's five forces model, patent analysis, key buying criteria, legal requirement, regulatory framework, and market attractiveness index have been studied in detail.
Market drivers like the increasing geriatric population, technological advancement, and the growing occurrence of autoimmune diseases are driving the injectable drug delivery market growth. However, the industry is facing market restraints, like the high manufacturing cost of the injectable drug delivery systems, which is obstructing the industry growth.
Key opportunities like the development of better injectable systems and an increase in the healthcare expenditure are driving the market growth. However, challenges such as developments in the alternate drug delivery systems and stringent rules are being faced by this market.
Geographies covered in the injectable drug delivery market by region are:
• North America: United States and Canada
• Europe: United Kingdom, Germany, Italy, Russia, Spain, France, and Rest of Europe
• Asia-Pacific: Japan, China, India, ASEAN countries, South Korea, Australia & New Zealand, and Rest of Asia-Pacific
• Latin America: Brazil, Mexico, and Rest of Latin America
• Middle East and Africa: Turkey, Saudi Arabia, South Africa, United Arab Emirates, and Rest of Middle East & Africa
The injectable drug delivery market has been segmented as follows:
• By Device type
o Pen injector
o Prefilled syringe
• Plastic-prefilled syringe
• Glass-prefilled syringe
o Auto injector
o Needle-free injector
• Gas-based needle-free injector
• Spring-based needle-free injector
• Other needle-free injectors
• By Route of Administration
o Subcutaneous
o Intravenous (IV)
o Intramuscular
o Other routes of administration
• By End-user
o Ambulatory care
o Clinics/physician offices
o Home-based
o Hospital
o Other end-users
The key players engaged in the injectable drug delivery market are Teva Pharmaceuticals, Baxter International Inc, Novo Nordisk A/S, Becton Dickinson and Company (BD), Gerresheimer, Terumo Corporation, Injex, Schott AG, Novartis AG, Eli Lilly and Company, Pfizer Inc, West Pharmaceuticals, Ypsomed Holding AG, Elcam Medical, and Sanofi SA.
The strategic analysis for each of these companies has been covered in detail. The injectable drug delivery market by company profiles helps to dive into the information about the key market players in this industry and how much of a hold they have on the market.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL INJECTABLE DRUG DELIVERY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. PORTER’S FIVE FORCES MODEL
2.2.1. THREAT OF NEW ENTRANT
2.2.2. THREAT OF SUBSTITUTE
2.2.3. BARGAINING POWER OF BUYERS
2.2.4. BARGAINING POWER OF SUPPLIERS
2.2.5. INTENSITY OF COMPETITIVE RIVALRY
2.3. PATENT ANALYSIS
2.4. KEY INSIGHT
2.5. KEY BUYING CRITERIA
2.6. LEGAL REQUIREMENT
2.7. REGULATORY FRAMEWORK
2.8. MARKET ATTRACTIVENESS INDEX
2.9. MARKET DRIVERS
2.9.1. INCREASING GERIATRIC POPULATION
2.9.2. TECHNOLOGICAL ADVANCEMENT
2.9.3. GROWING OCCURRENCE OF AUTOIMMUNE DISEASES
2.10. MARKET RESTRAINTS
2.10.1. HIGH MANUFACTURING COST OF INJECTABLE DRUG DELIVERY SYSTEMS
2.11. MARKET OPPORTUNITIES
2.11.1. DEVELOPMENT OF BETTER INJECTABLE SYSTEMS
2.11.2. INCREASE IN HEALTHCARE EXPENDITURE
2.12. MARKET CHALLENGES
2.12.1. DEVELOPMENTS IN ALTERNATE DRUG DELIVERY SYSTEMS
2.12.2. STRINGENT REGULATIONS
3. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY DEVICE TYPE
3.1. PEN INJECTOR
3.2. AUTO-INJECTOR
3.3. NEEDLE-FREE INJECTOR
3.3.1. SPRING-BASED NEEDLE-FREE INJECTOR
3.3.2. GAS-BASED NEEDLE-FREE INJECTOR
3.3.3. OTHER NEEDLE-FREE INJECTOR
3.4. PREFILLED SYRINGE
3.4.1. GLASS-PREFILLED SYRINGE
3.4.2. PLASTIC-PREFILLED SYRINGE
4. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY ROUTE OF ADMINISTRATION
4.1. SUBCUTANEOUS
4.2. INTRAMUSCULAR
4.3. INTRAVENOUS (IV)
4.4. OTHER ROUTE OF ADMINISTRATION
5. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY END-USER
5.1. CLINICS/ PHYSICIAN OFFICES
5.2. AMBULATORY CARE
5.3. HOSPITAL
5.4. HOME-BASED
5.5. OTHER END-USERS
6. INJECTABLE DRUG DELIVERY MARKET – REGIONAL OUTLOOK
6.1. NORTH AMERICA
6.1.1. MARKET BY DEVICE TYPE
6.1.2. MARKET BY ROUTE OF ADMINISTRATION
6.1.3. MARKET BY END-USER
6.1.4. COUNTRY ANALYSIS
6.1.4.1. UNITED STATES
6.1.4.2. CANADA
6.2. EUROPE
6.2.1. MARKET BY DEVICE TYPE
6.2.2. MARKET BY ROUTE OF ADMINISTRATION
6.2.3. MARKET BY END-USER
6.2.4. COUNTRY ANALYSIS
6.2.4.1. UNITED KINGDOM
6.2.4.2. GERMANY
6.2.4.3. FRANCE
6.2.4.4. ITALY
6.2.4.5. SPAIN
6.2.4.6. RUSSIA
6.2.4.7. REST OF EUROPE
6.3. ASIA-PACIFIC
6.3.1. MARKET BY DEVICE TYPE
6.3.2. MARKET BY ROUTE OF ADMINISTRATION
6.3.3. MARKET BY END-USER
6.3.4. COUNTRY ANALYSIS
6.3.4.1. JAPAN
6.3.4.2. CHINA
6.3.4.3. AUSTRALIA & NEW ZEALAND
6.3.4.4. INDIA
6.3.4.5. SOUTH KOREA
6.3.4.6. ASEAN COUNTRIES
6.3.4.7. REST OF ASIA-PACIFIC
6.4. LATIN AMERICA
6.4.1. MARKET BY DEVICE TYPE
6.4.2. MARKET BY ROUTE OF ADMINISTRATION
6.4.3. MARKET BY END-USER
6.4.4. COUNTRY ANALYSIS
6.4.4.1. BRAZIL
6.4.4.2. MEXICO
6.4.4.3. REST OF LATIN AMERICA
6.5. MIDDLE EAST AND AFRICA
6.5.1. MARKET BY DEVICE TYPE
6.5.2. MARKET BY ROUTE OF ADMINISTRATION
6.5.3. MARKET BY END-USER
6.5.4. COUNTRY ANALYSIS
6.5.4.1. SAUDI ARABIA
6.5.4.2. TURKEY
6.5.4.3. UNITED ARAB EMIRATES
6.5.4.4. SOUTH AFRICA
6.5.4.5. REST OF MIDDLE EAST & AFRICA
7. COMPANY PROFILES
7.1. BAXTER INTERNATIONAL INC
7.2. BECTON DICKINSON AND COMPANY (BD)
7.3. ELCAM MEDICAL
7.4. ELI LILLY AND COMPANY
7.5. GERRESHEIMER
7.6. INJEX
7.7. NOVARTIS AG
7.8. NOVO NORDISK A/S
7.9. PFIZER INC
7.10. SANOFI SA
7.11. SCHOTT AG
7.12. TERUMO CORPORATION
7.13. TEVA PHARMACEUTICALS
7.14. WEST PHARMACEUTICALS
7.15. YPSOMED HOLDING AG
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.1.1. OBJECTIVES OF STUDY
8.1.2. SCOPE OF STUDY
8.2. SOURCES OF DATA
8.2.1. PRIMARY DATA SOURCES
8.2.2. SECONDARY DATA SOURCES
8.3. RESEARCH METHODOLOGY
8.3.1. EVALUATION OF PROPOSED MARKET
8.3.2. IDENTIFICATION OF DATA SOURCES
8.3.3. ASSESSMENT OF MARKET DETERMINANTS
8.3.4. DATA COLLECTION
8.3.5. DATA VALIDATION & ANALYSIS
TABLE 1 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2019-2028 ($ MILLION)
TABLE 2 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)
TABLE 3 DIFFERENT TYPES OF INSULIN PEN INJECTORS
TABLE 4 MARKETED NEEDLE-FREE INJECTORS PRODUCTS
TABLE 5 GLOBAL NEEDLE-FREE INJECTOR BY TYPE, 2019-2028 ($ MILLION)
TABLE 6 LYOPHILIZED DRUGS WHICH ARE USED IN PREFILLED SYRINGE
TABLE 7 GLOBAL PREFILLED SYRINGE, BY TYPE, 2019-2028 ($ MILLION)
TABLE 8 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
TABLE 9 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)
TABLE 10 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2019-2028 ($ MILLION)
TABLE 11 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)
TABLE 12 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
TABLE 13 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)
TABLE 14 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)
TABLE 15 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)
TABLE 16 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
TABLE 17 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)
TABLE 18 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)
TABLE 19 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)
TABLE 20 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
TABLE 21 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)
TABLE 22 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)
TABLE 23 LATIN AMERICA INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)
TABLE 24 LATIN AMERICA INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
TABLE 25 LATIN AMERICA INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)
TABLE 26 LATIN AMERICA INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)
TABLE 27 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)
TABLE 28 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
TABLE 29 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)
TABLE 30 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)
FIGURE 1 GLOBAL INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 2 KEY BUYING IMPACT ANALYSIS
FIGURE 3 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY PEN INJECTOR, 2019-2028 ($ MILLION)
FIGURE 4 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY AUTO-INJECTOR, 2019-2028 ($ MILLION)
FIGURE 5 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)
FIGURE 6 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY SPRING-BASED NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)
FIGURE 7 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY GAS-BASED NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)
FIGURE 8 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY OTHER NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)
FIGURE 9 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY PREFILLED, 2019-2028 ($ MILLION)
FIGURE 10 GLOBAL PREFILLED SYRINGE MARKET, BY GLASS-PREFILLED SYRINGE, 2019-2028 ($ MILLION)
FIGURE 11 GLOBAL PREFILLED SYRINGES MARKET, BY PLASTIC-PREFILLED SYRINGE, 2019-2028 ($ MILLION)
FIGURE 12 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY SUBCUTANEOUS, 2019-2028 ($ MILLION)
FIGURE 13 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY INTRAMUSCULAR, 2019-2028 ($ MILLION)
FIGURE 14 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY INTRAVENOUS, 2019-2028 ($ MILLION)
FIGURE 15 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY OTHER ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
FIGURE 16 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY CLINICS/PHYSICIAN OFFICES, 2019-2028 ($ MILLION)
FIGURE 17 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY AMBULATORY CARE, 2019-2028 ($ MILLION)
FIGURE 18 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY HOSPITAL, 2019-2028 ($ MILLION)
FIGURE 19 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY HOME-BASED, 2019-2028 ($ MILLION)
FIGURE 20 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY OTHER END-USER, 2019-2028 ($ MILLION)
FIGURE 21 UNITED STATES INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 22 CANADA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 23 UNITED KINGDOM INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 24 GERMANY INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 25 FRANCE INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 26 ITALY INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 27 SPAIN INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 28 RUSSIA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 29 REST OF EUROPE INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 30 JAPAN INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 31 CHINA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 32 AUSTRALIA & NEW ZEALAND INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 33 INDIA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 34 SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 35 ASEAN COUNTRIES INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 36 REST OF ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 37 BRAZIL INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 38 MEXICO INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 39 REST OF LATIN AMERICA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 40 SAUDI ARABIA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 41 TURKEY INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 42 UNITED ARAB EMIRATES INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 43 SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 44 REST OF MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)